02.17.2014 - By The Lancet Group
Norbert Stefan discusses a small but positive trial of a new drug in people with non-alcoholic fatty liver disease.Continue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv